OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
600085$25.2358

600085.SS

PharmaceuticalsVerified

The company maintains a relatively strong liquidity position, with a current ratio of 3.59, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, the liquidity risk is assessed as medium, and the company has a negative net cash position after subtracting total debt, which could pose a challenge in the event of a liquidity crunch. Profitability metrics show a return on equity (ROE) of 8.71%, which is a strong indicator of the company's ability to generate returns for its shareholders. However, the return on assets (ROA) is lower at 3.88%, suggesting that the company may not be utilizing its assets as efficiently as it could. The gross profit margin is 42.3%, and the operating margin is 11.75%, both of which are in line with industry norms. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification could expose the company to higher risk if market conditions in its primary market deteriorate. The company's growth trajectory is expected to remain stable, with no significant changes in revenue or earnings projected for the next fiscal year. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on new assets. The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified. The risk assessment indicates that the company is not currently facing any major financial or operational risks that would significantly impact its operations or financial performance. Recent events, including analyst estimates and price targets, suggest a positive outlook for the company. The mean price target is 36.48 CNY, with a median price target of 37.46 CNY, indicating that analysts generally expect the stock to appreciate in value.

30-day price · 600085-2.57 (-9.2%)
Low$25.01High$28.45Close$25.23As of26 May, 00:00 UTC
Profile
Company600085.SS
Ticker600085.SS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

Classification. The company is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

The company maintains a relatively strong liquidity position, with a current ratio of 3.59, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, the liquidity risk is assessed as medium, and the company has a negative net cash position after subtracting total debt, which could pose a challenge in the event of a liquidity crunch. Profitability metrics show a return on equity (ROE) of 8.71%, which is a strong indicator of the company's ability to generate returns for its shareholders. However, the return on assets (ROA) is lower at 3.88%, suggesting that the company may not be utilizing its assets as efficiently as it could. The gross profit margin is 42.3%, and the operating margin is 11.75%, both of which are in line with industry norms. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification could expose the company to higher risk if market conditions in its primary market deteriorate. The company's growth trajectory is expected to remain stable, with no significant changes in revenue or earnings projected for the next fiscal year. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on new assets. The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified. The risk assessment indicates that the company is not currently facing any major financial or operational risks that would significantly impact its operations or financial performance. Recent events, including analyst estimates and price targets, suggest a positive outlook for the company. The mean price target is 36.48 CNY, with a median price target of 37.46 CNY, indicating that analysts generally expect the stock to appreciate in value.
Key takeaways
  • The company has a strong liquidity position with a current ratio of 3.59.
  • The company's ROE of 8.71% is strong, but its ROA of 3.88% is relatively low.
  • The company's revenue is concentrated in a single business segment, which could increase its risk exposure.
  • The company is expected to maintain a stable growth trajectory with no significant changes in revenue or earnings projected.
  • Analysts have a generally positive outlook for the company, with a mean price target of 36.48 CNY.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$17.26B
Gross profit$7.30B
Operating income$2.03B
Net income$1.19B
R&D
SG&A
D&A
SBC
Operating cash flow$2.69B
CapEx-$357.3M
Free cash flow$1.63B
Total assets$30.62B
Total liabilities$16.96B
Total equity$13.66B
Cash & equivalents
Long-term debt$4.26B
Valuation
Market price$25.23
Market cap$34.60B
Enterprise value$38.86B
P/E29.1
Reported non-GAAP P/E
EV/Revenue2.2
EV/Op income19.2
EV/OCF14.4
P/B2.5
P/Tangible book2.5
Tangible book$13.66B
Net cash-$4.26B
Current ratio3.6
Debt/Equity0.3
ROA3.9%
ROE8.7%
Cash conversion2.3%
CapEx/Revenue-2.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
Metric600085Activity
Op margin11.8%2.4% medp25 -91.8% · p75 12.5%above median
Net margin6.9%1.2% medp25 -98.4% · p75 10.4%above median
Gross margin42.3%45.6% medp25 29.8% · p75 66.7%below median
CapEx / revenue-2.1%-5.2% medp25 -15.8% · p75 -1.7%above median
Debt / equity31.0%9.3% medp25 0.1% · p75 43.8%above median
Observations
IR observations
Mean price target36.48 CNY
Median price target37.46 CNY
High price target45.54 CNY
Low price target25.00 CNY
Mean recommendation1.88 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count4.00
Hold count0.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate1.10 CNY
Last actual EPS0.87 CNY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 22:19 UTC#290b4a46
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 00:03 UTCJob: 98d3e58f